The second phase of the clinical trial of Sotorasib was successfully conducted by the Pharmaceutical Rapid Reading Society

February 1, 2021 / Medical Information At a Glance: The successful phase II clinical trial of Anjin Sotorasib; Daily fresh medicine news, speed reading society and you pay attention to! Part1 Policy Brief Beijing local zero new confirmed cases of overseas import January 31 from 0:00 to 24:00, Beijing no new locally confirmed cases, suspected cases and asymptomatic infected persons;
has carried out epidemiological investigations into the above-mentioned confirmed cases and implemented control measures as required.
(CCTV News) Jilin added 10 new confirmed cases of neo-crown pneumonia January 31 0-24 hours, Jilin Province found 4 new confirmed cases (1 case in Changchun City, 3 cases in Tonghua City), through the isolation of medical observers Active testing and screening was carried out, and 5 cases of asymptomatic infections reported in designated medical institutions were converted to confirmed cases (5 cases in Tonghua City), and 1 suspected case reported in Changchun City on 29 January was converted to confirmed cases.
9 confirmed cases (9 cases in Tonghua City) reached the standard of discharge from the hospital with neo-crown pneumonia and were cured and discharged from the hospital.
(Jilin Provincial Health Committee) Heilongjiang Province, 22 new confirmed cases on January 31, 2021 0-24, Heilongjiang Province, 22 new confirmed cases, distributed in: 9 cases in Wangkui County, Harbin City Hulan District 6 cases, Harbin City Limin Development Zone 3 cases, Harbin City Dauri District 2 cases, Harbin City Nangang District 2 cases.
9 new cases of asymptomatic infection on the same day (of which 6 cases were reported in Wangkui County, Harbin Hulan District, and 1 case in Harbin Limin Development Zone).
(Heilongjiang Provincial Health Commission) Part2 after observing the IPO application of Saisheng Pharmaceuticals through the Hong Kong Stock Exchange to hear the latest publicity on the HKEx website, Saisheng Pharmaceuticals IPO application has been heard by the Hong Kong Stock Exchange.
Pharmaceuticals filed an IPO application on the Hong Kong Stock Exchange in September 2020 under Section 8.12 of the Listing Rules, with the co-sponsors being COG, Morgan Stanley and Credit Suisse (Hong Kong).
according to the post-hearing information set, the HKEx IPO will be raised mainly for the acquisition or authorization of the introduction of new drug candidates, as well as to promote the development and commercialization of clinical stage drug candidates.
(Pharmaceutical Mission) Anglo Medical has submitted an application for listing to the Hong Kong Stock Exchange on February 1, according to a preliminary prospecto filed on January 29, Chinese personal protective equipment manufacturer Anglo Medical has submitted listing application information to the Hong Kong Stock Exchange.
(Anglo Medical Announcement) Rispley completed nearly 200 million yuan B round of financing Guoke investment lead investment on February 1, focusing on inhalation drug delivery technology application development of innovative pharmaceutical enterprises Rithpley recently announced that has completed a total amount of nearly 200 million yuan B round of financing.
this round of financing by the National Science Investment Leading Investment, Yuansheng Ventures, TongTron Weiye, the former jellyfish fund, Tianfeng Capital, Relying Capital and other well-known investment institutions with investment.
this round of financing will be mainly used to expand the company's existing GMP production line, high-end inhalation preparations and inhalation of innovative drugs and other pipeline layout.
on January 31st, Greenlee Pharmaceuticals announced that it had signed a contract with Hillhouse NEV, a fund owned by Gaoli Capital, to obtain HK$1.25 billion in financing from Gaoli Capital by means of a targeted new issue, which was a 10% premium to the closing price on the date of the agreement.
addition, Tsing Ting Capital also received the issued shares of the approved Greenlee Pharmaceuticals at the same price per share.
the total amount of the two transactions is HK$2.4 billion, after the completion of the transaction, Gao Yi Capital will hold 15.60% of the shares of Green leaf pharmaceutical.
(Green Leaf Pharmaceutical Announcement) Le Quasi-Chi Core completed 35 million yuan Pre-A round financing artery network was informed that on February 1, 2021, biochip and testing platform development enterprise "Le-Chi-Chi" announced the completion of 35 million yuan Pre-A round financing.
this round of financing by Sanno Bio-LED Investment, Shenzhen Ruihing Source and Investment, Beito Capital as the financial advisor of the transaction.
funds will be used to build production workshops and develop new products, and promote the company's chemical luminescent biochips, instruments and calcitonin original chemical luminescent kits and other products to market sales.
(Arterial Network) Bai Osaitu and Japan's LiberoThera reached a strategic cooperation agreement between Bai Osaitu and Japan's Libero Tera Co., Ltd. today announced that the two sides will be based on the World's most advanced all-human antibody mouse RenMab® antibody discovery platform and Libero Tera outstanding antigen preparation technology, to carry out a strategic cooperation for human GPCR antibody development.
(American News Agency) Deqi Pharmaceuticals and Pharmaceuticals Biology, United Pharmaceuticals started cooperation on February 1, Deqi Pharmaceuticals and Pharmaceuticals Biology, Pharmaceuticals announced that the three parties reached a strategic cooperation to jointly accelerate the development and production of innovative antibody coupling drugs.
this is the second time since October 2020 that Deqi Pharmaceuticals and Pharmaceuticals have reached a CDMO cooperation on dual-specific antibodies.
(Agency) Part3 Drug News Consino Bio announced positive results in the New Coronary Vaccine Phase 3 trial On February 1, Consino Bio announced that it had received notification from the Independent Data Monitoring Committee that phase 3 clinical trials of the recombinant new coronavirus vaccine had successfully met the pre-set primary safety and versus effectiveness standards in the medium-term analysis, without any serious adverse events related to the vaccine.
the successful clinical trial of Sotorasib Phase II non-small cell lung cancer, Amgen announced the success of Sotorasib Phase II CodeBreaK 100 lung cancer trial, which focused on 126 patients with advanced non-small cell lung cancer with KRAS G12C mutation.
CodeBreaK 100 trial, the objective response rate of the Sotorasib patient group was 37.1%, the disease control rate was 80.6%, and the medium response duration was 10 months.
Sotorasib is also the first KRASG12C inhibitor to prove progress-free survival.
(Sina Pharmaceutical News) Margenza significantly reduced the risk of disease progress/death recently, MacroGenics announced that the results of the critical Phase 3 SOPHIA study evaluating Margenza's treatment of breast cancer have been published in JAMA Oncology.
results showed that in patients with metastasis HER2-positive breast cancer who had previously received multiple anti-HER2 treatments, Margenza plus chemotherapy significantly reduced the risk of disease progress or death by 24% compared to Hersheyn-chemotherapy.
(Bio Valley) Gan Li Pharmaceuticals Phase 1 candidate drug was approved by the FDA Fast Track On February 1, Gan Li Pharmaceuticals announced that the FDA has awarded GLR2007 Fast Track Review Qualification for the treatment of glioblastoma patients.
GLR2007 is a cell cycle protein-dependent kinase 4/6 (CDK 4/6) inhibitor being developed by Ganli Pharmaceuticals for the treatment of advanced solid tumors, including glioblastoma.
(Agency) EU CHMP recommended approval of Xcopri: Assisted treatment of adult agency eclampsia Epilepsy Recently, Arvelle Therapeutics announced that the EMA Committee on Human Medical Products has issued a positive review recommending the approval of Xcopri, an anti-epileptic drug used in at least 2 anti-epileptic drugs previously treated but the condition has not been fully controlled in adult patients, assisted treatment of eclampsia.
(Bio Valley) pioneered nuclear output inhibitor Nexpovio EU is about to be approved Karyopharm Therapeutics recently announced that the EMA Committee on Human Medical Products has issued a positive review, recommending conditional approval of Nexpovio, joint Simisson, Used to treat adult patients with multiple myeloma who have received at least 4 therapies in the past and whose disease is difficult to treat with at least 2 protease inhibitors, 2 immunosuppressants, 1 anti-CD38 monoclonal antibody, and progression of the disease while receiving the last treatment.
(Bio Valley) powerful FGFR kinase inhibitor Pemazyre EU is about to be approved, Incyte announced that the EMA Human Pharmaceutical Products Committee has issued a positive review, recommending conditional approval of Pemazyre, the drug It is a selective fibroblast growth factor-receiving kinase inhibitor used to treat patients with local advanced or metastatic bile duct cancer who have relapsed or are difficult to treat after receiving at least one systematic therapy, where FGFR2 fusion or rearm is present and cannot be surgically removed.
(Bio Valley) Astellas leukemia new drug "Gigitini" approved in China NMPA official website latest publicity, Astellas Fumaric acid Giliteni tablets in China's listing application status has been updated to "approved - pending certification."
means the clinically urgent need for new drugs to be approved in China.
, according to the NMPA Drug Review Center, the application is for the treatment of adult patients with recurring or incurable acute myeloid leukemia with FLT3 mutation.
(Pharmaceutical Mission) Zhengda Pharmaceutical Afa osteoalin softgel was approved before the evaluation, NMPA official website shows that Zhengda Pharmaceutical (Qingdao) Afa osteotisol softgel to supplement the application was approved for evaluation, is the first domestic product evaluation enterprises.
data show that afa osteoalphrine is an active vitamin D, mainly used in osteoporosis, adrenal osteopathy, hyperthyroidism and other adaptive disorders.
(Minenet) Shanghai Pharma: Beetrobol tablets through generic drug consistency evaluation February 1, Shanghai Pharmaceuticals announced that recently, the holding subsidiary Xinyi Wandi received NMPA issued on the penicillin tablets of the "Drug Supplemental Application Approval Notice", the drug through generic drug quality and efficacy consistency evaluation.
canine tablets are mainly suitable for primary or secondary gyrations.
(Shanghai Pharmaceutical Bulletin) Respiratory syncytial virus prevention monoantigennirsevimab into the breakthrough treatment drug procedure According to the official website of the NMPA Drug Review Center recently announced, by Sanofi Pasteur and AstraZenecon jointly developed to prevent respiratory syncytial virus infection of the long-acting monoclonal antibody nirsevimab was officially approved to be included in the breakthrough treatment drug procedure.
Nirsevimab is suitable for all infants and young children who experience the first respiratory syncytial virus epidemic season, as well as children with chronic lung disease or congenital heart disease who experience the respiratory syncytial virus epidemic season for the first and second time.
(Medical Mission)